Cabaletta Bio (CABA)
(Delayed Data from NSDQ)
$4.26 USD
-0.28 (-6.17%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $4.25 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CABA 4.26 -0.28(-6.17%)
Will CABA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CABA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CABA
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
CABA: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'
Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade
Other News for CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PGIM Jennison Health Sciences Fund Q2 2024 Commentary
Cabaletta Bio price target lowered by $10 at Evercore ISI, here's why
Cabaletta Bio: Overweight Rating Maintained Amidst ICANS Incident and Adjusted Price Target
Cabaletta Bio price target lowered by $15 at Wells Fargo, here's why